Coordinated with clinical trials within the year to develop new corona vaccine Shionogi Pharmaceutical Co., Ltd. April 27, 18:31
Shionogi Pharmaceutical Co., Ltd., a major pharmaceutical company, has decided to embark on the development of a new coronavirus vaccine. We plan to start clinical trials by the end of the year and strengthen the system so that we can provide 10 million people as soon as possible from next year.
According to the announcement, Shionogi will start developing a vaccine that utilizes a technology called "recombinant protein" in cooperation with the National Institute of Infectious Diseases.
As a project with the highest priority, we will intensively invest funds and personnel, and we will proceed with coordination with the Ministry of Health, Labor and Welfare to start clinical trials to administer to humans within the year.
After receiving the vaccine approval, the company plans to strengthen the system for mass production so that it can provide 10 million people as soon as possible from next year.
“Recombinant protein” is a technology for producing a protein that recombines genetic information to obtain immunity to viruses, and is characterized by a short period from development to mass production.
According to WHO = World Health Organization, research institutes and companies in China and the United States are already conducting clinical trials regarding the development of a new coronavirus vaccine.
Even in Japan, the Daiichi Sankyo group of the University of Tokyo and a major pharmaceutical company and groups such as Osaka University are embarking on development, and there are active moves toward the provision of domestic vaccines.